Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Observational Safety Study for Nivolumab in China Routine Oncology Practice

NCT04825873 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT04825873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04825873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Observational Safety Study for Nivolumab in China Routine Oncology Practice
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
May 28, 2021
Completion date
February 13, 2023
Enrollment
3,102 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, squamous cell carcinoma of head and neck